Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + lenalidomide versus rituximab-chemotherapy in untreated follicular lymphoma
ACTRN12612001045808Phase 3Completed
- Sponsor
- The Lymphoma Academic Research Organisation
- Start
- Sep 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of rituximab, lenalidomide, cyclophosphamide, doxorubicin, vincristine and 1 more in follicular lymphoma (FL) (2 arms), sponsored by The Lymphoma Academic Research Organisation. Primary endpoints: Complete response rate and Progression-free survival. Started Sep 2014; status: completed.
02
Drugs
rituximablenalidomidecyclophosphamidedoxorubicinvincristine
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on ACTRN12612001045808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612001045808.